Literature DB >> 17899452

Treatment of breast cancer in older women.

Daniele Bernardi1, Domenico Errante, Enzo Gallligioni, Diana Crivellari, Antonio Bianco, Luigi Salvagno, Ian S Fentiman.   

Abstract

BACKGROUND: Breast carcinoma management in the elderly often differs from the management in younger women and there is considerable controversy about what constitutes appropriate cancer care for older women. This controversy is reflected in the persistence of age-dependent variations in care over time, with older women being less likely to receive definitive care for breast cancer. There has been a significant increase in the last years in the number of studies conducted in older patients with breast cancer. Although available age-specific clinical trials data demonstrate that treatment efficacy is not modified by age, this evidence is limited by the lack of inclusion of substantial numbers of older women, particularly those of advanced age and those with comorbidities.
METHOD: The literature-based evidence of the last 10 years was extensively reviewed on the main issues concerning the treatment of breast cancer in older women.
RESULTS: Surgical treatment in older patients has evolved from avoidance to mastectomy to breast-conserving surgery, similarly to younger patients. Given its negative effect on the quality of life, in the last few years the role of adjuvant radiotherapy has been questioned in elderly patients with breast cancer. Adjuvant chemotherapy benefit in older patients applies mainly to Estrogen-receptor-negative patients, while in Estrogen-receptor-positive patients a major role is played by endocrine treatment. New "elderly-friendly" drugs, that can help clinicians to reduce toxicity, are now available for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17899452     DOI: 10.1080/02841860701630234

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

Review 1.  Adjuvant therapy for women over age 65 with breast cancer.

Authors:  Marie-Luise Sautter-Bihl; Rainer Souchon; Bernd Gerber
Journal:  Dtsch Arztebl Int       Date:  2011-05-27       Impact factor: 5.594

2.  Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group.

Authors:  J Barinoff; A Traut; D Bauerschlag; J Bischoff; D Herr; K Lübbe; H-J Lück; N Maass; C Mundhenke; M Schmidt; K Schwedler; M Thill; J Steffen; S Loibl; G von Minckwitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

3.  Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database.

Authors:  Philippe Autier; Mathieu Boniol; Carlo La Vecchia; Carlo LaVecchia; Lars Vatten; Anna Gavin; Clarisse Héry; Mary Heanue
Journal:  BMJ       Date:  2010-08-11

Review 4.  Adjuvant chemotherapy for early breast cancer in the elderly.

Authors:  Mary Leung; Iulianna Shapira; Thomas Bradley; Daniel R Budman
Journal:  Curr Treat Options Oncol       Date:  2009-04-10

5.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database.

Authors:  Philippe Autier; Mathieu Boniol; Anna Gavin; Lars J Vatten
Journal:  BMJ       Date:  2011-07-28

6.  Age at diagnosis in relation to survival following breast cancer: a cohort study.

Authors:  Jasmine Brandt; Jens Peter Garne; Ingrid Tengrup; Jonas Manjer
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

7.  Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma.

Authors:  Seung Pil Jung; Jeong Eon Lee; Se Kyung Lee; Sangmin Kim; Min-Young Choi; Soo Youn Bae; Jiyoung Kim; Won Ho Kil; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Seok Jin Nam
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

Review 8.  Geriatric oncology: problems with under-treatment within this population.

Authors:  Divya Swaminathan; Vikram Swaminathan
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

9.  Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.

Authors:  Gabriel N Hortobagyi
Journal:  Breast Cancer Res       Date:  2018-10-19       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.